



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	mirikizumab
Brand name	Omvo TM
Dosage forms	300 mg/15 mL vial for intravenous injection 100 mg/1 mL pre-filled pen for subcutaneous injection 100 mg/1 mL pre-filled syringe for subcutaneous injection
Manufacturer	Eli Lilly Canada Inc.
Submission type	New Submission
Indication reviewed	For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus Kinase (JAK)-inhibitor.
Canada's Drug Agency (CDA-AMC) Clinical Reimbursement Reviews (CRR)	CDA-AMC recommended: to Reimburse with clinical criteria and/or conditions. Visit the CRR website for more details .
Drug Benefit Council (DBC)	The Drug Benefit Council (DBC) screens drug submissions under review by CDA-AMC CRR to determine whether a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry of Health's (the Ministry's) drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened mirikizumab for UC in June 2023. Since mirikizumab is similar to other drugs that

	were previously reviewed by DBC for UC, the Ministry may accept the CDEC's recommendation for mirikizumab for UC without further DBC review.
Drug Coverage Decision	<u>Limited Coverage benefit.</u>
Date	November 19, 2024
Reasons	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none"> • The drug demonstrated some advantage over placebo with respect to patients achieving clinical remission during the induction and maintenance phases of treatment and corticosteroid-free remission during the maintenance phase of treatment. • Based on CDA-AMC's assessment of the health economic evidence, Omvoh does not represent good value to the health care system at the public list price. • The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug and Health Technology Agency \(CADTH\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.